The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (1 analysts) rates it none, with a mean price target of $13.
Bluerock Homes Trust, Inc.
BHM · NYSE American · USD · Market cap $38M
Bluerock Homes Trust, Inc.
FAIL · Does not pass the screenPrice as of 23 Oct 2026Daily close, not a live quoteLast reviewed 5 days ago
Screened 2026-10-23 · the tape above runs as of 20:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price8.05 USD at the 23 Oct 2026 close
- Ethical screenDoes not pass
- Last reviewed23 Oct 2026 (5 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 8.05 against the desk's fair-value range, base estimate 13.00, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
Bluerock Homes Trust, Inc. holds its Markdown at $8.05. The statistical read favours the buyers, held for 2 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the buyers, held for 2 days |
| Price at the screen | $8.05 |
| Valuation | N/A trailing · N/A forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.42 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 1,014.30% | Below 33% | Interest-bearing debt is 1,014.3% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 415.18% | Below 33% | Interest-bearing cash and securities are 415.2% of assets, above the one-third limit. | Fail |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 7.65% | Below 5% | 7.6% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Bluerock Homes Trust,'s business is in a permissible area, but its interest-bearing debt is about 1014% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BHM's ethical verdict changes
Today BHM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 63.1% margin of safety to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| EPS, trailing | -3.25 |
| Revenue growth | +10.3%steady growth |
| Profit margin | 3.0%barely profitable |
| Return on equity | -5.5%not currently earning a positive return on equity |
| Dividend yield | 481.00% |
| Debt to equity | 0.60moderate, manageable leverage |
| Beta | 0.42barely tracks the market's swings |
| 52-week range | 8.05 - 14.81 |
| Market cap | $38M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBHM trades on NYSE American. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (1 analysts) rates it none, with a mean price target of $13.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (1 analysts) rates it none, with a mean price target of $13.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 12.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (1 analysts) rates it none, with a mean price target of $13.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (1 analysts) rates it none, with a mean price target of $13.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (1 analysts) rates it none, with a mean price target of $13.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (1 analysts) rates it none, with a mean price target of $13.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $11.49 | -15.5% | · | $845 | -15.5% |
| 2 months | $11.24 | -13.6% | · | $864 | -13.6% |
| 3 months | $10.49 | -7.5% | $0.13 | $937 | -6.3% |
| 6 months | $8.31 | +16.8% | $0.25 | $1,198 | +19.8% |
| 1 year | $11.79 | -17.6% | $0.50 | $866 | -13.4% |
| 2 years | $16.45 | -41.0% | $0.63 | $628 | -37.2% |
| 3 years | $14.19 | -31.6% | $1.63 | $799 | -20.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BHM does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.